Table 1.
Baseline characteristics of included studies (n = 36). TAVI, transcatheter aortic valve implantation.
| Study | Year | Study Design (Nr Centers) | Sample Size | Age (Years) | STS-Score (%) | Inclusion Period | Valve Type | Follow-Up (Months) * | Approach for TAVI | Mortality at 30 Days |
|---|---|---|---|---|---|---|---|---|---|---|
| De Carlo et al. [19] | 2012 | Retrospective (3) | 275 | 82.4 | na | Sep 2007–Jul 20120 | 100% MCV | 12 | na | 3% |
| Gensas et al. [20] | 2014 | Retrospective (18) | 353 | 82 | 14.4 | Jan 2008–Feb 2012 | 85.8% SE 14.2% BE |
60 | na | na |
| Mouillet et al. [21] | 2015 | Retrospective (29) | 833 | 82 | 14.1 | Jan 2010–Oct 2011 | 100% SE | 8 | na | 9.3% |
| Nazif et al. [22] | 2015 | Retrospective (21) |
1973 | 84.5 | 11.4 | May 2007–Sept 2011 | 100% BE | 12 | na | 6.6% |
| Rodriguez-Olivares et al. [23] | 2016 | Retrospective (1) | 302 | 81 | na | Nov 2005–Jan 2015 | 67.2% SE 21.2% BE 11.6% ME |
na | na | na |
| Gonska et al. [24] | 2017 | Retrospective (1) |
283 | 79.9 | 6.7 | na | 100% ES3 | na | na | na |
| Raelson et al. [25] | 2017 | Retrospective (1) |
578 | 85,5 | Na | Mar 2009–Dec 2014 | 21% SE 79% BE |
1 | na | na |
| Dumonteil et al. [26] | 2017 | Retrospective (14) |
250 | 84 | 6,3 | Oct 2012–May 2014 | 100% ME | 12 | 100% TF | 4% |
| Monteiro et al. [27] | 2017 | Retrospective (22) | 670 | 81.8 | 10.7 | Jan 2008–Jan 2015 | 74% MCV 26% ES |
na | 96% TF 4% others |
na |
| Pellegrini et al. [28] | 2018 | Retrospective (3) | 283 | 80.8 | 6 | Jan 2014–Jan 2016 | 100% SE | 12 | 100% TF | na |
| De-Torres-Alba et al. [29] | 2018 | Retrospective (1) | 606 | 81.6 | na | Jan 2014–Jan 2017 | 100% BE | na | na | na |
| Mangieri et al. [30] | 2018 | Retrospective (1) | 611 | 84.4 | 6.9 | Oct 2007–Jul 2015 | 51.7% BE 33.7% SE |
12 | na | na |
| Bhardwaj et al. [31] | 2018 | Retrospective (1) | 383 | 83 | 9 | Jan 2012–July 2016 | 82% BE 18% SE |
9 | 84% TF | na |
| Pellegrini et al. [32] | 2018 | Retrospective (3) | 709 | 81 | na | Jan 2014–Jan 2016 | 100% BE | na | 100% TF | 1.6% |
| Gaede et al. [33] | 2018 | Retrospective (1) |
1025 | 81.9 | na | 2010–2015 | na | 2.4 | na | na |
| Nadeem et al. [34] | 2018 | Retrospective (1) |
672 | 81.4 | 7.4 | 2011–2017 | na | 12 | na | na |
| Chamandi et al. [35] | 2018 | Prospective (9) |
1629 | 81.5 | 10.9 | May 2009–Feb 2015 | 50.3% BE 49.7% SE |
48 | na | 42.3% |
| Doshi et al. [36] | 2018 | Retrospective (na) | 8148 | 82.5 | na | Jan 2012–Dec 2014 | na | na | na | na |
| Vejpongsa et al. [37] | 2018 | Retrospective (na) | 18,400 | 81.2 | na | Jan 2012–Dec 2013 | na | na | TF 75.5% 24.5% TA |
na |
| Cresse et al. [38] | 2019 | Retrospective (1) | 386 | 83 | na | Apr 2008–Jun 2017 | na | na | na | na |
| Dolci et al. [39] | 2019 | Retrospective (1) |
266 | 80 | na | Feb 2014–Feb 2018 | 100% BE | 12 | 84% TF 16% TA |
na |
| Costa et al. [40] | 2019 | Prospective (1) |
1116 | 82 | 4.4 | June 2007–Feb 2018 | 61.8% SE 27.2% BE 0.5% ME 10.5% Others |
72 | 97% TF 3% others |
3.9% |
| Meduri et al. [41] | 2019 | Prospective (1) |
704 | 82.5 | 6.6 | na | 34% SE 66% ME |
12 | na | na |
| Du et al. [42] | 2020 | Retrospective (1) | 256 | 76.5 | 7.1 | Mar 2013–Oct 2018 | na | 12 | Na | 3.3% |
| Shivamurthy et al. [43] | 2020 | Retrospective (1) |
917 | 80 | na | Nov 2011–Feb 2017 | na | na | 89.7% TF 10.3% TA |
na |
| Studies reporting only on RBBB status in pacemaker population (n = 3) | ||||||||||
| Watanabe et al. [44] | 2016 | Prospective (9) | 749 | 85 | 6.9 | Oct 2013–Aug 2015 | 100% BE | 16.4 | 78.5% TF 18.8% TA 2.7% T iliac |
4% |
| Auffret et al. [45] | 2017 | Retrospective (na) | 3527 | 82 | na | na | 55.8% BE 44.2% SE |
23 | 79.6% TF 16.4% TA 1.9% T aortic 2.1% TS |
7.2% |
| Maeno et al. [46] | 2019 | Retrospective (1) | 659 | 83 | na | Jan 2013–Dec 2015 | 85% BE 15% SE |
19.1 | na | 2.6% |
| Studies reporting only on LBBB status in pacemaker population (n = 8) | ||||||||||
| Testa et al. [47] | 2013 | Retrospective (na) | 818 | 82 | na | Oct 2007–Apr 2011 | 100% SE | 9 | 88.6% TF 11.4% TS |
5.5% |
| Schymik et al. [48] | 2014 | Retrospective (1) | 624 | 82 | na | May 2008–Apr 2012 | 80.8% BE 19.2% SE |
12 | na | na |
| Urena et al. [49] | 2014 | Retrospective (4) | 668 | 79.5 | na | na | 100% BE | 13 | 2.8% TAortic 42.9% TA 54.3% TF |
na |
| Nazif et al. [50] | 2014 | Retrospective (21) | 1151 | 84 | 11.2 | Mar 2007–Mar 2009 | 100% BE | 12 | 57% TF 43% TA |
3.6% |
| Fischer et al. [51] | 2018 | Prospective (18) | 3404 | 81.5 | 5.9 | Feb 2005–Oct 2017 | 46% SE 54% BE |
22 | 82.2% TF 2.2% TS 14.2% TA 1.4% T aortic |
5.7% |
| Chamandi et al. [52] | 2019 | Retrospective (9) | 1020 | 80.5 | 6.6 | May 2007–Feb 2015 | 48% BE 52% SE |
36 | 84% TF 11% TA 2% Taortic 3% TS |
na |
| Nazif et al. [53] | 2019 | Retrospective (51) | 1179 | 81.2 | 5.5 | Dec 2011–Nov 2013 | 100% BE | 24 | 83.5% TF 16.5% Tthoracic |
1.3% |
| Hamandi et al. [54] | 2020 | Retrospective (1) | 424 | 82 | 7.6 | Jan 2012–Mar 2016 | 87% SE 13% BE |
12 | 85% TF 13% TA 3% TAortic |
1.3% |
Values are n (%), mean = SD, or median (interquartile range) as appropriate. * Follow-up is reported as mean or median as given by the authors. LBBB = left bundle branch block; RBBB = right bundle branch block; SE = self-expandable; BE = balloon-expandable; ME = mechanically-expandable; TF = trans-femoral; TS = trans-subclavian; TA = trans-apical; T iliac = trans-iliac; T aortic = trans-aortic.